Skip to main content
OpenTrials
Completed

NCT Number: NCT02854046

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome

Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year.

Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh.

Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited.

Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Calciphylaxis Calcinosis Calcium Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nantes

Nantes, 44093, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients ≥ 18 years with chronic renal failure with Glomerular Filtration Rate < 30ml/min/1,73m²
  • diagnosis of calciphylaxis between 2006 and 2016
  • living in the Regions of Bretagne, Pays de la Loire, Poitou-Charentes or Centre Val de Loire.

Exclusion criteria

  • realized biopsy in favor of differential diagnosis
  • significant arterial lesion of lesion area or differential diagnosis more valid
  • if the diagnosis is not based on the following criteria: 3 clinical criteria or 2 clinical criteria and biopsy in favor, criteria which are :
  • Patient in chronic hemodialysis or stade 4 chronic kidney disease
  • At least 2 painful sores and hardly curable with concomitant painful purpura
  • Sore and purpura localisation in trunk, extremities and penis.

Treatment and study plan

Calcific Uremic Arteriolopathy

Other

Primary outcomes

  1. Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome.

    Time frame: Up to 16 months

Secondary outcomes

  1. Study factors determining the patient outcome with calciphylaxis

    Time frame: Up to 16 months

  2. Study case control of risk factors in the subgroup of patients in extra renal replacement therapy

    Time frame: Up to 16 months

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort

Acronym: CalciWest

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Aug 3, 2016
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.